Primary Tumor Resection for M1a Stage Lung Cancer

Primary Tumor Resection for M1a Stage Lung Cancer With Occult Pleural Dissemination Discovered During Surgery: a Prospective, Single-arm, Multi-center, Phase Ⅱ Trial

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06547710

Acronym

ECTOP-1023

Enrollment

Registered

2024-08-09

Start date

2024-04-01

Completion date

2027-12-01

Last updated

2026-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer Metastatic, Surgical Resection

Brief summary

This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1023. This study aims to explore the safety and efficacy of primary lesion resection in the treatment of M1a stage lung cancer with pleural dissemination found during surgery, and to more accurately evaluate whether primary lesion resection can improve the OS and quality of life of the corresponding patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. Volunteer to participate in clinical research, willing to follow and able to complete all trial procedures; 2. Aged 18-80 years (including critical values) when signing the informed consent form; 3. ECOG score 0 or 1; 4. No previous lung cancer surgery; 5. Intraoperative or postoperative pathological confirmation of M1a stage lung cancer; 6. Occult pleural metastasis found during surgery; 7. First-time treatment and no radiotherapy or chemotherapy.

Exclusion criteria

1. The lesion cannot be completely removed surgically; 2. Cytological or histological pathology confirms other lung malignancies other than lung cancer; 3. Patients who have undergone lung cancer surgery before; 4. Patients who have received radiotherapy or chemotherapy and are not treatment-naive patients.

Design outcomes

Primary

Measure	Time frame	Description
Median overall survival	About 10months.	Median overall survival for M1a patients underging surgery.

Secondary

Measure	Time frame	Description
2-year overall survival	2 years	2-year overall survival
5-year overall survival	5 years	5-year overall survival
FEV1 and FVC	0.5 year	Preoperative lung function test

Countries

China

Contacts

CONTACTFangqiu Fu, MD

fufangqiu12@163.com021-64175590

Outcome results